NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.1800
0.00 (0.00%)
Mar 31, 2025, 3:29 PM EST

NKGen Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Net Income
-48.48-82.95-26.75-23.27
Depreciation & Amortization
1.281.21.211.24
Stock-Based Compensation
4.244.140.070.09
Other Operating Activities
16.6253.442.891.45
Change in Accounts Receivable
-0.03-0.030.11
Change in Accounts Payable
4.883.990.440.96
Change in Other Net Operating Assets
0.58-1.8-0.38-0.14
Operating Cash Flow
-20.87-21.95-22.56-19.55
Capital Expenditures
---0.1-0.4
Sale (Purchase) of Intangibles
-0.05-0.05-0.06-0.06
Investing Cash Flow
-0.02-0.05-0.16-0.46
Short-Term Debt Issued
-10.292320.5
Long-Term Debt Issued
-16.22--
Total Debt Issued
12.5726.512320.5
Short-Term Debt Repaid
--0.3-0.68-0.4
Total Debt Repaid
-2.43-0.3-0.68-0.4
Net Debt Issued (Repaid)
10.1426.2122.3320.1
Issuance of Common Stock
0.351.680.160.06
Other Financing Activities
1.59-5.73--
Financing Cash Flow
12.0822.1622.4920.16
Net Cash Flow
-8.80.16-0.230.15
Free Cash Flow
-20.87-21.95-22.66-19.95
Free Cash Flow Margin
---29425.97%-4683.33%
Free Cash Flow Per Share
-0.86-1.42-3.56-1.40
Levered Free Cash Flow
-31.3311.32-16.94-
Unlevered Free Cash Flow
-29.6911.78-15.5-
Change in Net Working Capital
15.6-25.081.4-
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.